All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
The vector of anti-CD22 chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target Human CD22. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-CD22 antibody linked to CD28 and CD3ζ signaling domains. And the vector product was designed for the treatment of Acute lymphoblastic leukemia (ALL).
CAR Construction : RFB4-CD28-41BB-CD3ζ Fig.1 Comparing the activation of RFB4 CAR with m971 CAR against the full-length CD22. RFB4 or m971 CAR-Jurkats were cocultured with Raji B cells (E:T=1:1) for 24 hrs. (B) IL-2 release was measured by ELISA and (C) CD69 expression was assessed by flow cytometry. Xiao, Q., Zhang, X., Tu, L., Cao, J., Hinrichs, C. S., & Su, X. (2022). Size-dependent activation of CAR-T cells. Science Immunology, 7(74), eabl3995. |
CAR Construction : Fig.2 Equilibrium-binding curves of murine RFB4 and huRFB4 IgG. Binding activity to CD22-positive Raji cells at indicated concentrations was determined by flow cytometry performing triplicate measurements. Bars represent standard errors (SEs) of mean values. Weber T, Mavratzas A, Kiesgen S, et al. A humanized anti-CD22-onconase antibody-drug conjugate mediates highly potent destruction of targeted tumor cells[J]. Journal of Immunology Research, 2015, 2015. |
More Published Data More Published Data
There are currently no customer reviews or questions for Anti-CD22 (RFB4) h(CD28-CD3ζ) CAR, pCDCAR1 (CAR-ZP2658). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION